• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Generics, Biosimilars Makers Join Global Medical Harmonisation Body

15/06/2016 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Doors to a global medical harmonisation organisation opened to the generic and biosimilar industry, which described it as an historical moment for them. The industry will now be able to sit on the assembly of the international body that joins regulators and the pharmaceutical industry.

At issue is the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). According to a press release, the ICH‘s General Assembly today approved the International Generic and Biosimilar Medicines Association (IGBA) as an ICH assembly member. ICH is a Geneva-based organisation that brings together regulatory authorities and the pharmaceutical industry.

The decision reflects the evolution of the generic and biosimilar pharmaceutical industries, with generics accounting for the majority of the prescriptions filled globally,” while the development and approval of biosimilars and other complex-to-manufacture medicines continue to expand,” according to the release.

Biosimilar products, also called follow-on biological products, or similar biotherapeutic products, are defined by the World Health Organization as: “a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.”

Beata Stepniewska, deputy director general and head of regulatory affairs for Medicines for Europe, told Intellectual Property Watch in an email, “Our industry expresses a strong interest in a rational and harmonized approach to generic drug development and quality to ensure positive impacts to global public health.”

“We are willing to contribute to elaboration of those standards,” she said, “particularly in the areas being critical for generic medicines industry like harmonised international standards for bioequivalence studies, future development of quality standards (including on APIs, finished products, excipients, manufacturing and GMP) and future telematics standards that have an impact on electronic submission of Marketing Authorisation Applications.”

“To join the ICH as an Assembly Member is a historical moment for our industry,” IGBA Chair Vivian Frittelli said in the release. “We strongly believe that, having contributed to the ICH work as an interested party during the last 20 years, we can now open a new chapter of engaging fully in the ICH activities of developing the international standards applied to the pharmaceutical industry, including generic and biosimilar manufacturers.”

In October, the ICH, during the inaugural meetings of its new Assembly, announced organisational changes, and in particular aiming at making the ICG “a truly global initiative,” according to ICH.

“More involvement from regulators around the world is welcomed and expected, as they will be invited to join counterparts from Europe, Japan, USA, Canada and Switzerland as ICH regulatory members,” said ICH. “This is matched by the possibility of wider inclusion of global industry sectors affected by ICH harmonization.”

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Generics, Biosimilars Makers Join Global Medical Harmonisation Body" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Health & IP, Other International Orgs, Patents/Designs/Trade Secrets

Trackbacks

  1. International Council on Harmonisation (ICH) Includes International Generic Trade Organization (IGBA) for the First Time | | FDA Life says:
    16/06/2016 at 4:03 pm

    […] Council for Harmonisation (ICH) (formerly the International Conference on Harmonisation) announced that the International Generic and Biosimilars Medicines Association (IGBA) (could join ICH as an […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.